Bitwise MARA Option Income Strategy ETF (NYSEARCA:IMRA) Short Interest Down 87.7% in March

Bitwise MARA Option Income Strategy ETF (NYSEARCA:IMRA) saw a large drop in short interest during the month of March. As of March 13th, there was short interest totaling 449 shares, a drop of 87.7% from the February 26th total of 3,660 shares. Based on an average daily trading volume, of 3,086 shares, the days-to-cover ratio is presently 0.1 days. Approximately 0.2% of the shares of the company are short sold. Approximately 0.2% of the shares of the company are short sold. Based on an average daily trading volume, of 3,086 shares, the days-to-cover ratio is presently 0.1 days.

Bitwise MARA Option Income Strategy ETF Price Performance

IMRA stock traded down $0.89 during midday trading on Tuesday, hitting $13.17. 13,032 shares of the stock traded hands, compared to its average volume of 5,949. Bitwise MARA Option Income Strategy ETF has a 1-year low of $11.99 and a 1-year high of $60.73. The stock’s fifty day simple moving average is $14.66 and its 200-day simple moving average is $22.87. The firm has a market cap of $3.16 million, a P/E ratio of 263.40 and a beta of -6.67.

Insider Buying and Selling

In other news, insider Helen Louise Collins sold 5,000 shares of the company’s stock in a transaction on Tuesday, March 17th. The shares were sold at an average price of $27.76, for a total value of $138,800.00. Following the sale, the insider directly owned 25,000 shares of the company’s stock, valued at $694,000. This represents a 16.67% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 37.30% of the company’s stock.

Bitwise MARA Option Income Strategy ETF Company Profile

IMARA Inc, a clinical-stage biopharmaceutical company, develops and commercializes therapeutics for patients with rare genetic disorders of hemoglobin. Its lead product candidate is IMR-687, an oral and once-a-day therapeutic that is in Phase 2b clinical trials for the treatment of sickle cell disease and ß-thalassemia. The company also develops IMR-261, an oral and clinical-ready activator of nuclear factor erythroid 2–related factor 2 for the treatment of hemoglobinopathies, iron disorders, and potentially other areas.